324 related articles for article (PubMed ID: 29544202)
1. Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E; Mercier T; Wagner AD; Homicsko K; Michielin O; Ellefsen-Lavoie K; Cagnon L; Diezi M; Buclin T; Widmer N; Csajka C; Decosterd L
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1083():124-136. PubMed ID: 29544202
[TBL] [Abstract][Full Text] [Related]
2. An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.
Rousset M; Titier K; Bouchet S; Dutriaux C; Pham-Ledard A; Prey S; Canal-Raffin M; Molimard M
Clin Chim Acta; 2017 Jul; 470():8-13. PubMed ID: 28412197
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry.
Nijenhuis CM; Haverkate H; Rosing H; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2016 Jun; 125():270-9. PubMed ID: 27058232
[TBL] [Abstract][Full Text] [Related]
4. Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS.
Krens SD; van der Meulen E; Jansman FGA; Burger DM; van Erp NP
Biomed Chromatogr; 2020 Mar; 34(3):e4758. PubMed ID: 31758580
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma.
Nijenhuis CM; Rosing H; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2014 Jan; 88():630-5. PubMed ID: 24216282
[TBL] [Abstract][Full Text] [Related]
6. Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study.
Gurav SD; Gilibili RR; Jeniffer S; Giri S; Srinivas NR; Mullangi R
Biomed Chromatogr; 2011 Jul; 25(7):794-800. PubMed ID: 20872957
[TBL] [Abstract][Full Text] [Related]
7. A high-performance liquid chromatography-tandem mass spectrometry method for simultaneous determination of imigliptin, its five metabolites and alogliptin in human plasma and urine and its application to a multiple-dose pharmacokinetic study.
Liu Y; Song L; Yao X; Wu Y; Liu H; Zhao Q; Jiang J; Shi C; Ma X; Zhou H; Liu D; Hu P
Biomed Chromatogr; 2018 Nov; 32(11):e4324. PubMed ID: 29952007
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a rapid and simple LC-MS/MS method for quantification of vemurafenib in human plasma: application to a human pharmacokinetic study.
Bihan K; Sauzay C; Goldwirt L; Charbonnier-Beaupel F; Hulot JS; Funck-Brentano C; Zahr N
Ther Drug Monit; 2015 Feb; 37(1):132-6. PubMed ID: 24977381
[TBL] [Abstract][Full Text] [Related]
10. Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma.
Vikingsson S; Dahlberg JO; Hansson J; Höiom V; Gréen H
Anal Bioanal Chem; 2017 Jun; 409(15):3749-3756. PubMed ID: 28429064
[TBL] [Abstract][Full Text] [Related]
11. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
Daud A; Gill J; Kamra S; Chen L; Ahuja A
J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS.
Huynh HH; Pressiat C; Sauvageon H; Madelaine I; Maslanka P; Lebbé C; Thieblemont C; Goldwirt L; Mourah S
Ther Drug Monit; 2017 Feb; 39(1):43-54. PubMed ID: 27861317
[TBL] [Abstract][Full Text] [Related]
13. Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.
Luethi D; Durmus S; Schinkel AH; Schellens JH; Beijnen JH; Sparidans RW
Biomed Chromatogr; 2014 Oct; 28(10):1366-70. PubMed ID: 24619951
[TBL] [Abstract][Full Text] [Related]
14. A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study.
Furlong MT; Agrawal S; Hawthorne D; Lago M; Unger S; Krueger L; Stouffer B
J Pharm Biomed Anal; 2012 Jan; 58():130-5. PubMed ID: 21982905
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.
Herbrink M; de Vries N; Rosing H; Huitema ADR; Nuijen B; Schellens JHM; Beijnen JH
Biomed Chromatogr; 2018 Apr; 32(4):. PubMed ID: 29165815
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry.
Liu X; Li W; Zhang Y; Jiang Y; Zhao Q; Zhong D
J Pharm Biomed Anal; 2019 Nov; 176():112735. PubMed ID: 31394305
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the effect of plasma albumin levels on regorafenib-induced hepatotoxicity using a validated liquid chromatography-tandem mass spectrometry method.
Pang YY; Tan YL; Ho HK
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1061-1062():220-224. PubMed ID: 28750235
[TBL] [Abstract][Full Text] [Related]
18. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients.
Zhao J; Yan D; Li Y; Xu X; Li F; Zhang S; Jin J; Qiu F
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Apr; 1237():124100. PubMed ID: 38547701
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry.
Jourdil JF; Tonini J; Stanke-Labesque F
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Mar; 919-920():1-9. PubMed ID: 23384531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
